Skip to content
Black Week: 20% off everything, code BLACK

Search

What are you looking for?

Type at least 2 characters to see suggestions.

Nootropics Marek Wawrzyk

Nootropic substances – what are they and when to use them?

The term "nootropics" today includes several groups of compounds with completely different origins, mechanisms and - what is most important in practice - with completely different legal status.

Laboratory test tubes

The term “nootropics” today includes several groups of compounds with completely different origins, mechanisms and – what is most important in practice – with completely different legal status. Caffeine, a prescription drug and a compound that is not approved for marketing in any form may appear in the same sentence. These are not equivalent categories and treating them together leads to errors.

This article organizes the cluster: what nootropics are in the strict sense, how the mechanisms are divided, what the data show in healthy people and – most extensively – what the map of the regulatory status in the European Union looks like. It does not contain doses, combination patterns or suggestions for use.

What are nootropics – definition and its limits

The term was coined in the 1970s by Romanian pharmacologist Corneliu Giurgea, describing compounds with a specific profile: improving learning and memory processes, protecting the brain, devoid of typical psychostimulating effects and characterized by low toxicity. The classic representative of this group was piracetam, and the pharmacology of the entire family was described in an extensive review (Gouliaev and Senning, 1994, PMID 8061686).

In everyday circulation, the definition has diverged from the original one. Today, a “nootropic” is any compound from which someone expects better mental performance – including strong stimulants, which Giurgea’s criterion explicitly excluded. It is worth remembering this when reading lists in which L-theanine and amphetamine-like substances are side by side.

Legal status – five groups, not one

This is the most important part of this article. The table below organizes the situation in the European Union. The groups differ not in the degree of risk, but in legal basis of trade – and these are two different things.

Group Examples Status in the EU
Food ingredients with established status caffeine, L-theanine, choline, Alpha-GPC approved for food circulation; Alpha-GPC assessed by EFSA as a novel food
Medicinal products piracetam (Nootropil, Memotropil), modafinil, choline alfoscerate (Gliatilin®, Delecit®) national registration, subject to medical prescription, indications strictly specified
Substances without authorization Huperzine A, phenylpiracetam, aniracetam, noopept, phenibut, bromantane, sulbutiamine not authorized as food and not registered as a medicinal product in the EU
Plant raw materials with disputed status kava (Piper methysticum) not on the EU list of novel foods; withdrawals and restrictions in some countries
Research reagents Semax, Selank, Dihexa, NSI-189 Research Use Only – no use in humans

Three notes without which this table can be misread.

First of all – “drug” does not mean “stronger supplement”. Piracetam is a registered medicinal product subject to medical prescription in Poland, but its registered indications are narrow: myoclonus of cortical origin, dyslexic disorders in children in combination with speech therapy and dizziness. Improving memory in a healthy adult is not a registered indication — even though it is with this use that the name “piracetam” is most often associated.

Secondly, the same molecule can be found in two groups at once. Alpha-GPC appears simultaneously as a food ingredient and as an active substance in a medicinal product. It is the commercial form and level of use that determines it, not the name itself. We develop this topic in a separate article on Alpha-GPC.

Thirdly – lack of authorization is not a formality. It means that no authority has assessed the safety of a given ingredient for food use, so there is no established level at which it is considered safe. This is not tantamount to a statement of harmfulness – it is a statement of lack of assessment.

Mechanisms – how nootropics are divided

Cholinergic

The most numerous and best described group. It works through the acetylcholine system, a neurotransmitter involved in memory encoding and maintaining attention. It is divided into two approaches with reverse logic:

  • Choline precursors — provide a substrate for the synthesis of acetylcholine. These include Alpha-GPC and citicoline (CDP-choline), whose profiles have been discussed in reviews on choline supplementation (Kansakar et al., 2023, PMID 36950691).
  • Acetylcholinesterase inhibitors — do not provide a substrate but inhibit the enzyme that breaks down acetylcholine. This includes huperzine A, assessed in a Cochrane review in the context of Alzheimer’s disease (Li et al., 2008, PMID 18425924).

Racetams and AMPA receptor modulators

This family of compounds is structurally derived from piracetam. Some of its representatives act as modulators of AMPA receptors involved in glutamatergic transmission – this mechanism has been described for aniracetam in studies on recombinant receptors (Johansen et al., 1995, PMID 7476926). The relationship between racetams and the cholinergic system is discussed separately (Pepeu and Spignoli, 1989, PMID 2694231). We describe the details of this group in the context of the formula combining phenylpiracetam, aniracetam and Alpha-GPC.

Stimulants and eugeroics

The group excluded by Giurgea’s original definition, today most often classified as nootropics. It includes caffeine, modafinil and compounds with dopaminergic effects. It is characterized by a mechanism of central excitation, not modulation of memory processes.

Plant and adaptogenic

Plant extracts with a diverse profile – from L-theanine from tea leaves to kavalactones from kava. It is the most heterogeneous group in terms of quality of evidence and regulatory status.

Mitochondrial

Compounds affecting cell energy metabolism, not synaptic transmission. This includes methylene blue, which has been reported to impact mitochondrial function and neuroprotective pathways in preclinical models (Tucker et al., 2018, PMID 28840449). Emoxypine, an antioxidant paired with succinate and registered as a medicine in Russia, has its own article: emoxypine (Mexidol).

Nootropic peptides: Semax, Selank, DSIP and related compounds

Structure alone sets nootropic peptides apart from racetams and cholinergic compounds: they are short chains of amino acids, not small molecules. The Russian-registered preparations in this group are nasal drops or solutions, not tablets. The data differ too: most studies come from a few Russian centers, often the developers’ own teams, with few independent replications.

  • Semax: a fragment of the hormone ACTH with an attached Pro-Gly-Pro tripeptide, registered in Russia since 1994 and prescription-only there today. Animal models describe its effects on BDNF, while healthy people have been studied only with fMRI. Details, including N-Acetyl Semax and Adamax: Semax peptide: mechanism and evidence.
  • Selank: tuftsin, an antibody fragment, extended by the same tripeptide. In Russia it is a non-prescription medicine, and three clinical studies there compared it with benzodiazepines or added it to them; none was placebo-controlled. More, including N-Acetyl Selank and Adalank: Selank, N-Acetyl Selank and Adalank.
  • DSIP: the delta sleep-inducing peptide, isolated in 1977. Independent studies did not confirm a clinically significant effect on sleep, and no gene or receptor has been identified. It is the active substance of Russia’s Deltaran, registered for combination therapy of stress-related conditions and alcohol withdrawal: DSIP, the delta sleep-inducing peptide.

The group also includes Cortagen, the tetrapeptide Ala-Glu-Asp-Pro from the same “peptide bioregulator” school as Epitalon. It is described mainly in animal and cell studies (Kazakova et al., 2002, PMID 12447482). The whole family and the quality of its evidence are covered in a separate article on Cortagen and peptide bioregulators. Dihexa, by contrast, is an angiotensin IV derivative with a different lineage. In 2025 the journal retracted three papers by its developers, including the one describing its mechanism of action (Benoist et al., 2014, PMID 25187433). The paper on its procognitive effect has carried an expression of concern since 2021 (McCoy et al., 2013, PMID 23055539).

None of these peptides is an approved medicine in the EU or the US, and those in our catalog are research reagents intended solely for laboratory research. FDA lists Semax, Selank, DSIP and Dihexa among peptides nominated for pharmacy compounding, noting that it lacks important safety information on each (FDA, 2026). Russian registrations take Semax, Selank and DSIP out of class S0 of the WADA List without settling their status in sport, so each is discussed separately. Derivatives with no registration in any country, such as the N-acetylated variants, Adamax or Adalank, are prohibited in sport at all times.

What do the data show in healthy people

It is worth separating two situations that merge into one in marketing materials: data from clinical populations (diagnosed people with reduced cognitive function) and data in healthy people. Improvement in the former does not automatically transfer to the latter.

A series of meta-analyses examining the effects of single administration on cognitive function in healthy adults were performed for the best-studied substances in this category, including modafinil, methylphenidate, and D-amphetamine (Roberts et al., 2020, PMID 32709551). A previous systematic review examined modafinil in sleep-deprived subjects (Battleday and Brem, 2015, PMID 26381811). The conclusions from this literature are much more cautious than the image established in popular culture – the effects are sometimes small, depending on the task and the initial level of performance.

A separate systematic review was conducted on the use of cognitive enhancement drugs among college students (Sharif et al., 2021, PMID 33802176). We discuss this population in more detail in the material about nootropic substances in the context of science.

The best documented combination in this category remains caffeine with L-theanine, for which a systematic review with a meta-analysis of randomized trials is available (Payne et al., 2025, PMID 40314930), based on previous observations on attention and mood (Owen et al., 2008, PMID 18681988). At the same time, it is the combination with the least problematic regulatory status – both ingredients belong to the first group from the table.

What is actually in the product

In this category, the issue of compliance of the composition with the label is not a marginal issue, but one of the main problems.

The analysis published in Neurology: Clinical Practice examined products sold as preparations supporting cognitive functions and detected five unapproved medicinal substances – including omiberacetam, vinpocetine, phenibut and picamilon – in some cases in amounts different from the declared ones, and in part without declaration on the label (Cohen et al., 2021, PMID 34484905).

A broader picture is provided by an overview devoted to unauthorized ingredients of nootropic preparations, including the history of this group, pharmacology, prevalence, international regulations and doping potential (Jędrejko et al., 2023, PMID 37357012). A separate study analyzes adulteration of “brain health” preparations by the addition of medicinal substances (Paiva et al., 2024, PMID 38540898).

The practical conclusion is the same as in other categories with weak supervision: the identity of the material is determined by the analytical documentation of the batch, not the name on the packaging.

Anti-Doping Notice

Some compounds in this category are on the WADA Prohibited List. This includes, among others, phenylpiracetam (under the name fonturacetam, historically carphedon), modafinil and bromantane — all in category S6, stimulants. Anti-doping rules are not limited to professionals: in Poland, the Prohibited List is in force through the Polish Anti-Doping Agency (POLADA), and amateur competitors taking part in competitions covered by these rules are also subject to control.

A general clause applies – failure to mention a compound by name does not mean approval, because the ban also covers substances with a similar chemical structure or similar biological effect. The current status should always be verified in the applicable version of the Prohibited List.

Where to find details

This article serves as a map. We develop individual threads separately:

  • Alpha-GPC — monograph of a single compound: cholinergic mechanism, difference from citicoline, double regulatory status.
  • Phenylpiracetam, aniracetam and Alpha-GPC — racetams and an example of a formula in which the ingredients belong to different regulatory groups.
  • Nootropics and science — kava, huperzine, sulbutiamine and methylene blue; data on the student population.

Frequently asked questions

Are all nootropics dietary supplements?

No. This category also includes food ingredients with an established status, registered medicinal products subject to medical prescription, substances without any authorization and research reagents. These are four different legal bases for trade.

Does piracetam improve memory in healthy people?

Piracetam is a registered drug in Poland, but its registration indications include myoclonus of cortical origin, dyslexic disorders in children in combination with speech therapy and vertigo. Improving memory in a healthy adult is off-label.

What does it mean that an ingredient is not authorized as a food?

That no authority has assessed its safety for food use and no safe level has been established. This is not a statement of harmfulness, but a statement of lack of judgment.

Are nootropics detected in doping control?

Yes. Phenylpiracetam (fonturacetam), modafinil and bromantane are on the WADA Prohibited List in category S6. There is also a clause covering substances with a similar structure or similar effect.

Why does the article not provide doses or combination methods?

Because there is no established dosage for most of the substances in question – its determination is the result of the registration process, which these compounds have not undergone. For the rest, the criteria for admission are specific to their category, not the list in the article.

Summary

Nootropics are not a homogeneous category and the biggest misunderstandings come from treating them as one group. In the European Union, there are at least four separate legal bases for trade – from food ingredients with an established status, through registered medicinal products subject to medical prescription, to substances without any authorization and reagents intended only for research. The same molecule can belong to two groups at once, depending on the commercial form and level of use. In terms of evidence, the best documented combination remains caffeine with L-theanine, for which a systematic review with meta-analysis of randomized trials is available; for substances most often associated with “improving cognitive functions”, meta-analyses in healthy adults provide significantly more conservative conclusions than the popular picture. A separate and real problem in this category is the compliance of the composition with the label, documented many times in the analytical literature.

Product documentation

Material cards together with analytical documentation of the batch are available in the category advanced nootropics. Materials intended for adults; some of them are reagents for research use only.

Bibliography

  1. Gouliaev AH, Senning A. Piracetam and other structurally related nootropics. Brain Res Brain Res Rev. 1994;19(2):180-222. PMID: 8061686
  2. Jędrejko K, Catlin O, Stewart T, Anderson A, Muszyńska B, Catlin DH. Unauthorized ingredients in “nootropic” dietary supplements: A review of the history, pharmacology, prevalence, international regulations, and potential as doping agents. Drug Test Anal. 2023;15(8):803-839. PMID: 37357012
  3. Cohen PA, Avula B, Wang YH, Zakharevich I, Khan I. Five Unapproved Drugs Found in Cognitive Enhancement Supplements. Neurol Clin Pract. 2021;11(3):e303-e307. PMID: 34484905
  4. Paiva R, Correia M, Delerue-Matos C, Amaral JS. Adulteration of Brain Health (Cognitive, Mood, and Sleep Enhancement) Food Supplements by the Addition of Pharmaceutical Drugs: A Comprehensive Review of Analytical Approaches and Trends. Foods. 2024;13(6):908. PMID: 38540898
  5. Roberts CA, Jones A, Sumnall H, Gage SH, Montgomery C. How effective are pharmaceuticals for cognitive enhancement in healthy adults? A series of meta-analyses of cognitive performance during acute administration of modafinil, methylphenidate and D-amphetamine. Eur Neuropsychopharmacol. 2020;38:40-62. PMID: 32709551
  6. Battleday RM, Brem AK. Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: A systematic review. Eur Neuropsychopharmacol. 2015;25(11):1865-1881. PMID: 26381811
  7. Sharif S, Guirguis A, Fergus S, Schifano F. The Use and Impact of Cognitive Enhancers among University Students: A Systematic Review. Brain Sci. 2021;11(3):355. PMID: 33802176
  8. Payne ER, Aceves-Martins M, Dubost J, Greyling A, de Roos B. Effects of Tea (Camellia sinensis) or its Bioactive Compounds l-Theanine or l-Theanine plus Caffeine on Cognition, Sleep, and Mood in Healthy Participants: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutr Rev. 2025;83(10):1873-1891. PMID: 40314930
  9. Owen GN, Parnell H, De Bruin EA, Rycroft JA. The combined effects of L-theanine and caffeine on cognitive performance and mood. Nutr Neurosci. 2008;11(4):193-198. PMID: 18681988
  10. Kansakar U, Trimarco V, Mone P, Varzideh F, Lombardi A, Santulli G. Choline supplements: An update. Front Endocrinol (Lausanne). 2023;14:1148166. PMID: 36950691
  11. Li J, Wu HM, Zhou RL, Liu GJ, Dong BR. Huperzine A for Alzheimer’s disease. Cochrane Database Syst Rev. 2008;(2):CD005592. PMID: 18425924
  12. Johansen TH, Chaudhary A, Verdoorn TA. Interactions among GYKI-52466, cyclothiazide, and aniracetam at recombinant AMPA and kainate receptors. Mol Pharmacol. 1995;48(5):946-955. PMID: 7476926
  13. Pepeu G, Spignoli G. Nootropic drugs and brain cholinergic mechanisms. Prog Neuropsychopharmacol Biol Psychiatry. 1989;13 Suppl:S77-S88. PMID: 2694231
  14. Tucker D, Lu Y, Zhang Q. From Mitochondrial Function to Neuroprotection-an Emerging Role for Methylene Blue. Mol Neurobiol. 2018;55(6):5137-5153. PMID: 28840449
  15. Kazakova TB, Barabanova SV, Khavinson VKh, Glushikhina MS, Parkhomenko EP, Malinin VV, et al. In vitro effect of short peptides on expression of interleukin-2 gene in splenocytes. Bull Exp Biol Med. 2002;133(6):614-616. PMID: 12447482
  16. Benoist CC, Kawas LH, Zhu M, Tyson KA, Stillmaker L, Appleyard SM, et al. The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-met system. J Pharmacol Exp Ther. 2014;351(2):390-402. Retracted in 2025 (retraction notice: PMID 40312093). PMID: 25187433
  17. McCoy AT, Benoist CC, Wright JW, Kawas LH, Bule-Ghogare JM, Zhu M, et al. Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. J Pharmacol Exp Ther. 2013;344(1):141-154. Expression of concern published in 2021 (PMID 34551989). PMID: 23055539
  18. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of 22 April 2026). fda.gov (accessed 27 October 2026)